Jaguar Health shares surge 11.21% after-hours as EU regulatory progress for Canalevia diarrhea treatment submission sparks optimism.

Jaguar Health surged 11.21% in after-hours trading following its Italian subsidiary Napo Therapeutics’ submission of a request to the European Medicines Agency (EMA) for scientific advice on pursuing EU approval of Canalevia for general diarrhea in dogs. The move is based on updated analysis from a 2017 study showing improved outcomes for dogs treated with Canalevia compared to placebo. The company highlighted the lack of FDA-approved treatments for general canine diarrhea, a significant unmet medical need, and emphasized potential market access across 27 EU member countries if the EMA agrees with the analysis. The news aligns with Jaguar’s strategy to expand Canalevia’s commercialization beyond its conditional FDA approval for chemotherapy-induced diarrhea, positioning it for a larger market opportunity.